Ocular Therapeutix

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OCUL and other ETFs, options, and stocks.

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. 

CEO
Pravin U. Dugel
CEOPravin U. Dugel
Employees
274
Employees274
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2006
Founded2006
Employees
274
Employees274

OCUL Key Statistics

Market cap
2.40B
Market cap2.40B
Price-Earnings ratio
-7.85
Price-Earnings ratio-7.85
Dividend yield
Dividend yield
Average volume
6.54M
Average volume6.54M
High today
$11.92
High today$11.92
Low today
$10.77
Low today$10.77
Open price
$11.18
Open price$11.18
Volume
6.65M
Volume6.65M
52 Week high
$16.44
52 Week high$16.44
52 Week low
$5.79
52 Week low$5.79

Stock Snapshot

The current Ocular Therapeutix(OCUL) stock price is $11.27, with a market capitalization of 2.4B. The stock trades at a price-to-earnings (P/E) ratio of -7.85.

As of 2026-01-18, Ocular Therapeutix(OCUL) stock has fluctuated between $10.77 and $11.92. The current price stands at $11.27, placing the stock +4.7% above today's low and -5.5% off the high.

The Ocular Therapeutix(OCUL)'s current trading volume is 6.65M, compared to an average daily volume of 6.54M.

During the past year, Ocular Therapeutix(OCUL) stock moved between $5.79 at its lowest and $16.44 at its peak.

During the past year, Ocular Therapeutix(OCUL) stock moved between $5.79 at its lowest and $16.44 at its peak.

OCUL News

Nasdaq 2d
First Week of OCUL September 18th Options Trading

Investors in Ocular Therapeutix Inc (Symbol: OCUL) saw new options become available this week, for the September 18th expiration. One of the key inputs that goe...

First Week of OCUL September 18th Options Trading
Simply Wall St 2d
Ocular Therapeutix Valuation After XPaxley Progress And FDA Timeline Optimism

Recent enthusiasm around Ocular Therapeutix (OCUL) has been tied to progress on its XPaxley treatment for wet age related macular degeneration, together with ex...

Ocular Therapeutix Valuation After XPaxley Progress And FDA Timeline Optimism

Analyst ratings

100%

of 13 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own OCUL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .